Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Angelica, Quartino"'
Autor:
Samira Jamalian, Michael Dolton, Pascal Chanu, Vidya Ramakrishnan, Yesenia Franco, Kristin Wildsmith, Paul Manser, Edmond Teng, Jin Y. Jin, Angelica Quartino, Joy C. Hsu, for the Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 7, Pp 1029-1042 (2023)
Abstract There is strong interest in developing predictive models to better understand individual heterogeneity and disease progression in Alzheimer's disease (AD). We have built upon previous longitudinal AD progression models, using a nonlinear, mi
Externí odkaz:
https://doaj.org/article/3b249fe4407842a7bf2bc7d8b35b90cc
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 1, Pp 62-73 (2023)
Abstract Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the
Externí odkaz:
https://doaj.org/article/6c9f800424f0462f8528114142c69f0a
Autor:
Robin J Svensson, Jakob Ribbing, Naoki Kotani, Michael Dolton, Shweta Vadhavkar, Dorothy Cheung, Tracy Staton, David F Choy, Wendy Putnam, Jin Jin, Nageshwar Budha, Mats O. Karlsson, Angelica Quartino, Rui Zhu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1221-1235 (2021)
Abstract Identification of covariates, including biomarkers, spirometry, and diaries/questionnaires, that predict asthma exacerbations would allow better clinical predictions, shorter phase II trials and inform decisions on phase III design, and/or i
Externí odkaz:
https://doaj.org/article/99d33c6d1f7e4cdfb4ba2b342953726c
Autor:
Phyllis Chan, Han Ting Ding, Bianca M. Liederer, Jialin Mao, Paula Belloni, Liuxi Chen, Simon S. Gao, Victory Joseph, Xiaoying Yang, Joseph S. Lin, Mayur S. Mitra, Wendy S. Putnam, Angelica Quartino, Rebecca N. Bauer, Lin Pan
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1945-1954 (2021)
Abstract GDC‐0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), a promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK) profile and pharmacody
Externí odkaz:
https://doaj.org/article/38338915571446a38eeb11b03b47d34b
Autor:
Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin, Angelica Quartino
Publikováno v:
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-12 (2020)
Abstract Background Crenezumab, a fully humanized anti-beta-amyloid (Aβ) immunoglobulin G4 (IgG4) monoclonal antibody, binds to both monomeric and aggregated forms of Aβ. We assessed the pharmacokinetics (PK)/pharmacodynamics (PD) of crenezumab and
Externí odkaz:
https://doaj.org/article/2c76e3b461714d7fb634c9deff89de51
Autor:
Stephen Salloway, Lee A. Honigberg, William Cho, Michael Ward, Michel Friesenhahn, Flavia Brunstein, Angelica Quartino, David Clayton, Deborah Mortensen, Tobias Bittner, Carole Ho, Christina Rabe, Stephen P. Schauer, Kristin R. Wildsmith, Reina N. Fuji, Shehnaaz Suliman, Eric M. Reiman, Kewei Chen, Robert Paul
Publikováno v:
Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-13 (2018)
Abstract Background We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moder
Externí odkaz:
https://doaj.org/article/a311ee7ca9264e6696bffa8520f93ab9
Autor:
Rui Zhu, Angelica Quartino, Matts Kågedal, Wenhui Zhang, Meina T. Tang, Tong Lu, Sonoko Kawakatsu
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 49:179-190
Clinical trials in patients with ulcerative colitis (UC) face the challenge of high and variable placebo response rates. The Mayo Clinical Score (MCS) is used widely as the primary endpoint in clinical trials to describe the clinical status of patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d20fde35d0bec463dc5d0bb2847b17
https://doi.org/10.1007/s10928-021-09789-2
https://doi.org/10.1007/s10928-021-09789-2
Autor:
Han Ting Ding, Wendy S. Putnam, Simon S. Gao, Joseph Lin, Bianca M. Liederer, Jialin Mao, Angelica Quartino, Victory Joseph, Xiaoying Yang, Liuxi Chen, Paula Belloni, Phyllis Chan, Rebecca N. Bauer, Mayur S. Mitra, Lin Pan
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1945-1954 (2021)
Clinical and Translational Science
Clinical and Translational Science
GDC‐0334 is a novel small molecule inhibitor of transient receptor potential cation channel member A1 (TRPA1), a promising therapeutic target for many nervous system and respiratory diseases. The pharmacokinetic (PK) profile and pharmacodynamic (PD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e14caea2d2691c3e776c7ba0522c5ea6
https://doaj.org/article/38338915571446a38eeb11b03b47d34b
https://doaj.org/article/38338915571446a38eeb11b03b47d34b
Autor:
Amanda Roden, Nan Hu, Logan Brooks, Monica K Wetzel-Smith, Montserrat Carrasco-Triguero, Geoffrey A. Kerchner, Michael J. Dolton, Kathleen Blondeau, Jill Smith, Ariel Waitz, Anita Moein, Kaycee M Sink, Angelica Quartino, Aaron Chesterman, Kun Peng, Ajay Deshmukh, Susanne Ostrowitzki
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:1337-1348
Compared with intravenous formulations, subcutaneous (s.c.) formulations of therapeutic monoclonal antibodies may provide increased patient access and more convenient administration options, although historically high-volume s.c. administration (> 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b222931c1ce53bd4112e16a60b1ec2
https://doi.org/10.1002/cpt.2385
https://doi.org/10.1002/cpt.2385
Autor:
Susanne Ostrowitzki, Tobias Bittner, Kaycee M. Sink, Howard Mackey, Christina Rabe, Lawrence S. Honig, Emanuele Cassetta, Michael Woodward, Mercè Boada, Christopher H. van Dyck, Timo Grimmer, Dennis J. Selkoe, Andres Schneider, Kathleen Blondeau, Nan Hu, Angelica Quartino, David Clayton, Michael Dolton, Yifan Dang, Beth Ostaszewski, Sandra M. Sanabria-Bohórquez, Michael Rabbia, Balazs Toth, Udo Eichenlaub, Jillian Smith, Lee A. Honigberg, Rachelle S. Doody
Publikováno v:
JAMA neurology. 79(11)
ImportanceAlzheimer disease (AD), a neurodegenerative disease characterized by β-amyloid plaques and τ tangles in the brain, represents an unmet medical need with no fully approved therapeutics to modify disease progression.ObjectiveTo investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::173bd06a5f646f9e109a57dd1b9fccff
https://pubmed.ncbi.nlm.nih.gov/36121669
https://pubmed.ncbi.nlm.nih.gov/36121669